




10/50 132



INVESTOR IN PEOPLE

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**BEST AVAILABLE COPY**

Signed

*P. Mahoney*

Dated 12 February 2003



The  
**Patent  
Office**

**1/77**

The Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1.	Your reference	59.75481			
2.	Patent application number (The Patent Office will fill in this part)	<div>15 JAN 2002</div> <div><b>0200828.2</b></div> <div>16 JAN 02 E688036-1 D00027 F01/7700 0.00-0200828.2</div>			
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	<div>Matforsk Norwegian Food Research Institute Osloveien 1 N-1430 Ås Norway</div> <div>05990544001 Patents ADP number (if you know it)</div> <div>If the applicant is a corporate body, give country/state of incorporation</div>			
4.	Title of the invention	Methods of Nucleic Acid Amplification			
5.	Name of your agent (if you have one)	Frank B. Dehn & Co.			
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL			
	Patents ADP number (if you know it)	166001 ✓			
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	<table border="0"> <tr> <th>Country</th> <th>Priority application number (if you know it)</th> <th>Date of filing (day / month / year)</th> </tr> </table>	Country	Priority application number (if you know it)	Date of filing (day / month / year)
Country	Priority application number (if you know it)	Date of filing (day / month / year)			
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	<table border="0"> <tr> <th>Number of earlier application</th> <th>Date of filing (day / month / year)</th> </tr> </table>	Number of earlier application	Date of filing (day / month / year)	
Number of earlier application	Date of filing (day / month / year)				
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes			

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 30

Claim(s) 0

Abstract 0

Drawing(s) 14 + 14

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Frank B. Deane etc

Signature

Date 15 January 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Rebecca Gardner  
01273 244200

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

75481

METHODS OF NUCLEIC ACID AMPLIFICATION

The present invention relates to methods of nucleic acid amplification, in particular to methods that employ the polymerase chain reaction (PCR).

DNA amplification techniques, and in particular the polymerase chain reaction (PCR) have become key diagnostic tools. Theoretically, a single target molecule can be detected in a background of  $10^{10}$  to  $10^{12}$  non-target molecules. Recently, technology has been developed that allows nucleic acid quantification by monitoring the PCR amplification reaction in real-time (Orlando, C.P. Pinzani, and M. Pazzagli. 1998. Clin Chem Lab Med. 36(5):255-69.). There have also been efforts in the amplification of several targets simultaneously (multiplex PCR) (Elnifro, E.M., A.M. Ashshi, R.J. Cooper, and P.E. Klapper. 2000. Clin Microbiol Rev. 13(4):559-70.). This, however, is very complicated since several different primer pairs have to be optimised simultaneously.

While there is a demand in many diagnostic and other fields for multiplex PCR, the optimisation of multiplex PCR poses several problems, including poor sensitivity or specificity and/or preferential amplification of certain targets. Primers with better than average priming efficiency will produce more of their product and potentially use up the available triphosphates in the reaction mixture before amplicons relying on other less efficient primers reach detectable levels.

In addition, the presence of more than one primer pair in the multiplex PCR reaction increases the chance of obtaining spurious amplification products, primarily through the formation of primer dimers. These non-

specific products may be amplified more efficiently than the desired target, consuming reaction components and producing impaired rates of annealing and extension. The optimisation of multiplex PCR should aim to minimise or reduce such non-specific interactions.

Most diagnostic assays require detection and quantification of several different targets simultaneously. The methodological limitations, are in many cases the reasons for developing simplex assays, or assays including only a few targets. This is for instance the case with the current tests for genetically modified organisms (GMOs, essentially plant material) in foods. Currently, about 50 GMO constructs are approved in for commercial use in USA. In Europe, approved GMO foods require labelling if more than 1 % of any ingredient originates from a GMO. Considering the large numbers of GMOs expected in the future, multiplex quantitative measurements are required to determine whether the foods contain approved or unapproved GMO constructs, and whether the amount of GMO in the ingredients is above or below 1 %.

Thus, while multiplex PCR is a very useful technique in theory, the practical problems of simultaneously performing multiple reactions are holding back its use. Recently, a technique has been proposed (Shuber, A.P., V.J. Grondin, and K.W. Klinger. 1995. Genome Res. 5(5):488-93.) which seeks to reduce the impact of the different amplification efficiencies of different primers. Such methods involve the performance of two distinct PCR reactions, with different amplification primers used in each reaction. The primers used in the first reaction are bipartite, each containing a region which is specific for a particular target sequence within the nucleic acid sample to be analysed and a universal region at the 5' end.

Amplification cycles are performed to generate a population of amplicons from each target sequence. The region which is specific for a given target sequence hybridizes to the sample nucleic acid so that normal polymerase controlled extension can occur. The universal region does not hybridise with the original template nucleic acid but as products from earlier cycles are used as templates, this constant segment and regions complementary to it are incorporated into the amplicons. This helps to normalize the hybridisation kinetics across the different target sequences being simultaneously amplified, preventing individual target sequences being significantly over or under represented at the end of the reaction.

Then a second amplification reaction is performed using as primers oligonucleotides which comprise or consists of the universal region from the first amplification reaction. The different target regions are thus amplified using the same primers and the ratio of the number of starting molecules to end product amplicons should therefore be constant.

Such a method is described, for example in WO 99/58721 which is incorporated herein by reference. This publication particularly addresses the problems of amplifying and detecting many different target sequences in a single reaction and success is attributed to a combination of factors, including the small size of the amplification targets, optimization of amplification conditions and the presence of the constant (universal) sequence at the 5'-end of the primers.

However, in practice the methods described in WO 99/58721 and in J.Med.Genet 2000: 37 272-280, do not provide quantitative results in a multiplex PCR system.

There are many scenarios where as well as testing a sample for the presence of a number of different nucleic acid sequences of interest (multiplex), it is desirable to determine the level of each sequence in a sample, i.e. to obtain quantitative results. Of particular interest is the need for food producers and food control authorities to test whether foods and food ingredients contain genetically modified plants. Already about 50 different genetically modified plants have been approved in the USA and it would clearly be very costly and time consuming to analyse a food sample for specific genetically modified plants (gmps) in a series of separate reactions. As the number of gmps increases and their use become more widespread it will be desirable to use multiplex assays to detect signature genetic elements used in gmps in a single reaction. It is also desirable to have information about whether the specific group is present in the food only in trace amounts or whether the amount is above or below a certain limit. At present there are no methods available which reliably provide this quantitative information in a multiplex environment.

A method has now been developed which addresses these problems and has been shown to provide quantitative multiplex PCR in the context of detecting gmps and which also has general applicability to assays where quantitative results of multiplex PCR are required. The method is based on the two step PCR described above but it has surprisingly been found that removal of the primers from the first amplification reaction ensures that the second amplification reaction, and thus the method as a whole, retains its quantitative

character.

Thus, according to one aspect, the present invention provides a method of simultaneously amplifying a plurality of target sequences within sample nucleic acid which comprises:

(a) contacting said sample nucleic acid with one or more primer pairs under conditions which allow hybridisation of the primers to the sample nucleic acid, each primer having a bipartite structure A-B wherein part A is specific for a particular target sequence within the sample nucleic acid and part B is a constant sequence which is common to all primers or is common amongst all forward primers with a different sequence common amongst all reverse primers;

(b) performing a first amplification reaction;

(c) separating the bipartite primers from the amplification products of the first amplification reaction;

(d) contacting the amplification products from the first amplification reaction with primers which comprise part B of the bipartite primers under conditions which allow hybridisation of the primers to the amplification products; and

(e) performing a second amplification reaction.

In a preferred embodiment, the constant region B of the bipartite primers is common between both forward and reverse primers and thus only a single primer species is required in the second amplification reaction. In an alternative embodiment, it may be desirable to have different forward and reverse primers, with one of the primer species labelled for subsequent detection. Whether the constant region (B) is common to all primers or only amongst the forward or reverse primers, it is found at the 5' end of both the forward and reverse primers; the variable section (A) which is designed to



hybridise to a sequence in the sample nucleic acid is found at the 3' end of the bipartite primers. Thus the abbreviation 'A-B' does not imply a relative position within the molecule for the two regions in terms of the 3' and 5' ends. The constant region (B) is typically 10-40 nucleotides in length, preferably 12-25 nucleotides in length.

The region B will either be substantially the same in all bipartite primers or substantially the same amongst the forward primers with a second region B' which is different to B but is substantially the same amongst all the reverse primers. Preferably B (or B') will be exactly the same in all bipartite primers or at least in all forward or all reverse primers but it will be understood that a small number of nucleotide variations between sequences will not significantly affect the method. The term 'common' should be interpreted with this in mind. The purpose of these constant regions is to even out differences in priming efficiency and to provide highly efficient hybridisation and priming with the primers used in the second amplification reaction. Therefore between B sequences which are substantially the same there will preferably be variation at no more than 3 nucleotide positions.

Preferably the constant region(s) B is chosen so that it does not hybridise with the sample nucleic acid, or at least does not hybridise efficiently therewith. Thus a randomly chosen sequence may be constructed according to the well known rules for primer design.

Part A of the bipartite primers is specific for particular target sequences in that they are designed to hybridise to a region of nucleic acid which flanks the target sequence which it is desired to amplify. According to the normal conventions of the PCR, the A sequences will be in pairs, each pair consisting of a

forward primer and a reverse primer which hybridise to regions upstream and downstream of a nucleotide sequence of interest. The bipartite primers will therefore be formed into pairs of forward and reverse primers by the nature of their A sequence. The primers may have the form  $A^{F1}-B$ ,  $A^{R1}-B$ ,  $A^{F2}-B$ ,  $A^{R2}-B$  etc. where ' $A^{F1}$ ' indicates a forward primer sequence which hybridises to a flanking region of a first target sequence and  $A^{R1}$  a reverse primer sequence which hybridises to the other flanking region of the first target sequence. As mentioned above, the common regions B may be different in forward and reverse primers, thus having the form  $A^{F1}-B$ ,  $A^{R1}-B'$ ,  $A^{F2}-B$ ,  $A^{R2}-B'$  and so on.

The part A regions which hybridise to specific regions in the sample nucleic acid amplification are selected by methods well known in the field of nucleic acid amplification. In order to select a pair of A sequences for amplifying a target region, the sequence of and adjacent to the target sequence must be known (or at least approximately known). Short stretch sequences at either end of the target sequence are then selected and the primers designed for hybridisation to these regions.

Typically only a few cycles will be performed in the first amplification reaction, e.g. less than 25, preferably less than 15 to avoid potential artefacts in the multiplex amplification and to ensure that none of the targets reach saturation levels. Preferably this first amplification reaction is carried out using standard PCR reagents and conditions and suitable parameters for the cycles are described in the examples and are generally well known in the art.

To increase amplification efficiency for a given target sequence, the primer concentrations for that target may be increased for the first amplification

reaction.

The bipartite primers are then separated from the ~~amplification products of the first amplification~~ reaction before the second amplification reaction takes place. This may be achieved by removing the bipartite primers, conveniently this is done by breaking down the bipartite primers e.g. by exonuclease degradation. Alternatively the amplification products may be isolated from the rest of the initial reaction mixture which contains the bipartite primers. The products of the first amplification reaction are thus purified before being used as templates for the second amplification reaction. Purification is conveniently achieved by capturing the amplification products on a solid support, e.g. through attaching a binding moiety to the amplification products and providing a binding partner for said binding moiety on the solid support. The binding moiety may be attached to a probe which in turn hybridises to the amplification product. Suitable binding moieties are well known in the art and include, streptavidin/biotin, antigen/antibody interactions, lectin binding systems or probes covalently bound to a solid support etc. Suitable solid supports are also well known and widely available, preferably the support is magnetic and particulate for ease of manipulation.

It may be desirable to perform all the steps in one reaction vessel and degradation of the bipartite primers may conveniently allow this.

Key to the separation step is the fact that all or most, i.e. at least 70%, preferably at least 80% of the bipartite primers are separated from the amplification products before the second amplification reaction takes place.

The second amplification reaction uses either a single primer species or a single forward primer species

and a single reverse primer species. The advantages of such an approach are twofold. One limitation of multiplex PCR is the different amplification efficiencies of the different amplicons when specific primer sets are used. This will lead to a situation where some of the amplicons present are amplified whereas others are not. In addition, using many different primer pairs in one reaction inevitably leads to a large number of side reactions due to primers interacting with each other. These side reactions perturb the PCR. The use of a constant part B in the first step primers in combination with the removal of those primers eliminates these problems. Secondly, the amplification of all targets with the same primer or primer pair leads to a constant ratio of the different targets in the multiplex PCR before and after amplification, in the same way as in competitive PCR. By effectively removing the bipartite primers after the first PCR step, these do not interfere with the ratios of the different amplicons during the second PCR step. This removal is what makes the system maintain its quantitative nature.

"Amplification" refers to a process for using polymerase and a pair of primers for increasing the amount of a particular nucleic acid sequence, a target sequence, relative to the amount of that sequence initially present in the sample nucleic acid. Amplification may conveniently be achieved by the *in vitro* methods of PCR (including reverse transcriptase PCR (RT-PCR)) or ligase chain reaction or others as well as NASBA (nucleic acid sequence based amplifications) approaches.

A 'target sequence' is a sequence that lies between the hybridisation regions of a pair of primers (and may in addition include the primer sequences themselves) and

can be amplified by them. The number of different target sequences within the sample which may be amplified will depend on the nature and requirements of the assay. Typically there will be more than 4, e.g. 8 or more even 12 or 20 or more different target sequences amplified in one multiplex reaction.

In the context of assaying for the presence of GMOs, the target sequences may fall into one of a number of categories. The target sequence may fall entirely within a gene of interest and the ampicillin PCR in the multiplex system described in the present Examples is an example of this. The ampicillin resistance gene is included in pUC18 which is used in the generation of Bt176 corn (Maximizer Corn). A positive PCR result shows the presence of the gene but does not determine the origin of the DNA and therefore the amp signal could originate from Bt176 DNA but could also originate from a bacterial contamination of the plant.

A gene of interest is typically part of a construct of interest and a promoter often used in such constructs is the 35S promoter from the Cauliflower mosaic virus (CaMV). One of the PCRs in the multiplex PCR described in the present examples detects this promoter and thus target sequences may be in regulatory regions. Although again, a positive result may indicate that the plant has been infected with Cauliflower mosaic virus. The nos reaction of the present examples detects a different regulatory region used in these constructs, the NOS terminator.

A more specific approach is to design a primer pair overlapping a junction region between a promoter or terminator (a regulatory region) and a gene of interest.

These DNAs do not occur naturally in nature and thus a PCR signal would be a very strong indication of the presence of GMOs. In the present examples such an

overlap is detected in the multiplex PCR system for Bt176 and Bt11 (Methods for the specific detection of Bt176 corn and Bt11 corn are described in Hurst, C.D. et al. (1999) European Food Research and Technology Vol. 5, 579-586 and Zimmermann, A. et al. (2000) Lebensmittel-Wissenschaft & Technologie, 33, 210-216 respectively). In the Bt176 PCR a fragment overlapping the junction between the pepC promoter (phosphoenol pyruvate carboxylase promoter from maize) and the cry gene (a synthetic gene from *Bacillus thuringiensis* which confers insect resistance) is targetted. In Bt11 the PCR overlaps the junction between the 35S promoter and an enhancer DNA fragment from the alcohol dehydrogenase gene from maize. In a preferred embodiment of the present invention, one or more of the target sequences spans a non-naturally occurring nucleic acid sequence, e.g. a sequence comprising regions which are not naturally found in juxtaposition.

However, even this approach could conceivably cause problems if a company used the same construct, e.g. a specific promoter-enhancer-gene-terminator in several different plants (be it the same species or not, but different transformation events). One of these transformations (GMOs) may be approved by the relevant regulatory body while others are not but the PCR would not be able to discriminate between the approved GMO and the non-approved GMO(s). When a plant is transformed, DNA integrates randomly at different sites for each transformation event. Thus a way of overcoming the problems discussed above would be to determine the plant DNA sequence which flanks the inserted DNA, and then construct a primer pair which overlaps this junction (which can be called an 'event specific region').

Thus in a preferred embodiment of the methods of the present invention one or more of the target

sequences is for an event specific region, i.e. spans a region which comprises both host plant species DNA and ~~inserted DNA from the genetically engineered construct.~~

The Mon810 PCR of the present examples is an example of such an event specific region (Zimmermann et al. (1998)) Food Science and Tech. 31, 664-667 have designed a nested PCR system for the detection of Maisgard corn (Mon810 corn) as the amplified sequence lies in the overlap between integrated DNA and the plant's endogenous DNA.

The sample nucleic acid may be isolated or may exist as part of a mixed sample which includes other cellular components from the biological source from which it was obtained. Methods of isolating nucleic acid from a biological sample are well known in the art. Any biological sample containing nucleic acid is a suitable source of nucleic acid and thus the sample may be derived from animals, plants, insects, bacteria, yeast, viruses or other organisms. Particularly preferred sources of sample nucleic acid for amplification according to the present invention are plants or food products which contain or are suspected of containing genetically modified material. The 'sample nucleic acid' may be derived from one or more biological samples. In the context of plants and foodstuffs for example, a single plant may provide the sample nucleic acid or it may be derived from a number of plants of the same or even different species.

By 'nucleic acid' is meant DNA (including cDNA) or RNA. The nucleic acid may be naturally occurring or synthesised by chemical or recombinant techniques.

The above amplification method is then generally followed by a detection step and suitable detection methods for multiplex PCR are known in the art and discussed, for example, in WO 99/58721. When performing

a multiplex reaction it is necessary to differentiate between the amplification products from different loci.

This could be done on the basis of size discrimination, e.g. on gels but requires the amplification products to be of different sizes, e.g. 100 bp, 200 bp etc. The reaction products could be differentially labelled, i.e. different tags are attached to primers for different loci, however such a technique is limited by the number of different commercially available tags (e.g. fluorescent molecules).

Thus in a preferred embodiment probes specific to the different nucleotide sequences of interest which have been amplified are enzymatically labelled at their 3' end and then the labelled probes are captured by hybridisation to complementary DNA on a solid support e.g. nylon filters, glass slides, chips etc. Such methods are described in the Examples and in WO 99/50448.

These probes to the different target regions may be labelled at the 5'-end with a fluorescent group other than the one used in the 3'-end labelling reaction. During fluorescent scanning it would then be possible to calculate immediately the percentage of molecules labelled during the labelling reaction.

As discussed above, the methods claimed herein are quantitative in nature. The signal strengths for identified target sequences can be compared to known standards to calculate the concentration (e.g. copy number) of that target sequence in the sample. As described in the Examples, a known concentration of a control sequence (IPC) may conveniently be added to the sample to adjust for fluctuations in amplification efficiency from one sample reaction mix to another; the use of such an internal control determines the absolute amount of nucleic acid in the sample and is a preferred



embodiment of the present invention. In a further preferred embodiment, also described in the Examples, a ~~species-specific target sequence is amplified and this~~ reference gene enables the relative amounts of nucleic acid constructs/sequences of interest (e.g. a target GM construct) as compared to the material from said species to be determined.

Thus, the invention provides data for a given target sequence which can be quantified against a known reference for that target sequence. Target sequences can be detected qualitatively and quantitatively according to the methods of the invention and the results from different experiments compared because quantifiable information is obtained.

In a further aspect, the present invention provides a kit for use in a method of nucleic acid amplification, typically any method as described above, which comprises:

- (a) a plurality of bipartite primer pairs of form A-B as defined above;
- (b) means for removing said bipartite primers from the reaction mix; and
- (c) primers which comprise part B of the bipartite primers of component (a).

The invention will be further described in the following non-limiting examples and with reference to the Figures in which:

**Figure 1** provides a schematic representation of the quantitative multiplex amplification method. (A): In the first PCR step, the targets are amplified with primers containing "heads" that are equal for all the targets. (B): The "head"-containing primers are then removed by enzymatic digestion (left) or the amplified products are hybridized to an internal biotinylated capture probe and

the complex is then purified through binding to biotinylated paramagnetic beads (right). These are two independent alternative purification strategies. (C): In the second PCR step, a primer identical to the "head" sequence is used.

**Figure 2** provides a schematic illustration of the test format is. The probes complementary to the labelled test probes used in the enzymatic labelling are spotted horizontally using a grid. During hybridisation the grid is turned 90 degrees before application of hybridisation solutions and labelled probes.

**Figure 3** shows multiplex detection of GMO corn samples. GM corn DNA was analysed either alone or in combinations. Line 1: detection of the corn reference DNA, line 2: Mon810 signals, Line 3: Bt11 signals, Line 4: Bt176 signals. The samples analysed are indicated under the corresponding lanes (all analyses in duplicate), Lane 1,2: non GMO maize, lane 3, 4: 0.4 % Bt176, 0.7 % Bt11 and 0.4% Mon810 DNA, lane 5, 6: 1% Bt11 and 0,5% Bt176, lane 7, 8: 1% Mon810, lane 9,10: 1% Bt176, lane 11, 12: 2% Bt11.

**Figure 4** shows quantitative chromogenic detection of Bt11 corn DNA using the multiplex assay. 2% Bt11 corn DNA was diluted in non GM corn DNA to give different concentrations of GM corn. The results show the quantitative response of the assay as the concentration of GM corn is lowered. The first line shows the corn DNA reference signals, the second row shows the Bt11 signals. The signals were recorded on a Typhoon scanner, PE systems.

**Figure 5** shows eight-plex detection of GM maize. Eight specific primer pairs with "heads" were used in the first PCR step. The lines represent (from above): Bt 176, Bt11, Mon810, amp, Nos terminator, 35S promoter, Internal PCR control (IPC) and maize reference gene.

**Figure 6** shows quantitative multiplex PCR for detection of GM corn and the necessity of removing primers after the 1. PCR step. Each line shows the detection of a specific PCR product as indicated to the left. Each lane (a through l) represent different samples. All samples (a-j) contained a mixture of 0.7 % Bt176 and 0.7 % Bt11. In addition Mon 810 corn DNA was added to 2.0 % (lanes a, b), 1.0 % (lanes c, d), 0.5 % (lanes e, f), 0.2 % (lanes g, h) and 0.0 % (lanes i, j). In addition all lanes (a-l) contained approx. 100 copies of an internal positive control (IPC) DNA. Amp: ampicillin resistance gene from the pUC18. Nos: No's terminator, 35S: Cauliflower mosaic virus promoter.

(A): PCR carried out in two steps: 1. PCR (10 cycles) using specific primers with a common "head" sequence. Primers are then digested and the 2. PCR (30 cycles) is carried out using the common head primer. (B) Same as A, but the specific primers were not degraded before the 2. PCR step. Panel I: shows the fluorescence signals after hybridisation and scanning, panel II: shows the blot after binding of antibodies and enzymatic HRP colour reaction.

**Figure 7** illustrates the effect of omitting the 2. PCR step. Same as in Fig. 6A, except that the 1. PCR step using the specific primers with head sequence was extended to 40 cycles and the 2. PCR step was omitted. Panel A shows the fluorescence signals after

hybridisation and scanning, panel B shows the blot after binding of antibodies and enzymatic HRP colour reaction.

**Figure 8** illustrates the effect of diluting the template DNA. A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810 at different dilutions was used as templates in the PCR. Panel I shows the fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 1,2: undiluted DNA template, lanes 3, 4:  $\frac{1}{4}$  dilution, lanes 5,6: 1/16 dilution, lane 7, 8: 1/64 dilution, lanes 9,10: 1/256 dilution, lanes 11,12: no template added.

**Figure 9** shows quantitative 8-plex detection of Mon810 DNA alone (A) or together with 2 % Bt11 DNA (B). Panel I shows the fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 01, 02: A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810. Lane 1a, 1b: 5% Mon810, lanes:2, 3: 2% Mon810, lanes 4, 5: 1.0 % Mon810, lanes 6, 7: 0,5% Mon810, lanes 8, 9: 0,1% Mon810, lanes 10, 11: 0 % Mon810, lanes 12, 13: IPC (date 020901).

**Figure 10** shows the relationship between amount of Mon810 maize in a sample and the signal strength. The Mon810 fluorescence signals in Fig.9 panel I, were quantified using Imagemaker program and plotted against the given concentration of the samples.

**Figure 11** illustrates quantitative 8-plex detection of Mon810 DNA alone (A) or together with 2 % Bt11 DNA (B). Repetition of example 6 (Fig. 9). Panel I shows the

fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 01, 02: A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810. Lane 1a, 1b: 5% Mon810, lanes: 2, 3: 2% Mon810, lanes 4, 5: 1.0 % Mon810, lanes 6, 7: 0.5% Mon810, lanes 8, 9: 0.1% Mon810, lanes 10, 11: 0 % Mon810, lanes 12, 13: IPC (date 130901).

**Figure 12** shows the relationship between amount of Mon810 maize in a sample and the signal strength. The Mon810 fluorescence signals from the experiment in Fig.11 were quantified using Imagemaker program and plotted against the given concentration of the samples. The average of 2 parallels are shown.

**Figure 13** illustrates quantitative 8-plex detection of Bt176 DNA alone (A) or together with 1 % Mon810 DNA (B). Panel I shows the fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 1, 2: A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810. Lane 3, 4: 2% Bt176, lanes: 5, 6: 1% Bt176, lanes 7, 8: 0.5 % Bt176, lanes 9, 10: 0.2% Bt176, lanes 11, 12: 0.1% Bt176, lanes 13, 14: 0 % Bt176, lanes 15, 16: IPC (date 060901).

**Figure 14** shows the relationship between amount of Bt176 maize in a sample and the fluorescence signal strength. The Bt176 fluorescence signals from the experiment in Fig.13 were quantified using Imagemaker program and plotted against the given concentration of the samples. The average of 2 parallels are shown.

## **EXAMPLES**

### **MATERIALS AND METHODS**

#### **Template and DNA purification.**

The method chosen exploits the use of DNA adsorption columns provided by Qiagen in the DNeasy plant mini kit. Samples were homogenised when necessary and purified as described by the manufacturer with the following modifications.

The initial buffer volume was doubled and lysis was carried out for 30 min at 65 °C using a shaking incubator. When eluting DNA bound to the column, 50 µl of preheated buffer was used. In the repeated elution step another 50 µl buffer was added and the columns were spun at 13000 rpm for 2 min.

The criteria used for assessing the quality of the DNA preparation was that no inhibition should be detected when samples were analysed with different BioInside kits. This is easily seen on the internal PCR Control (IPC) provided by BioInside. Also the quality of DNA was analysed carrying out PCR on dilutions of a sample and calculating the amplification efficiency and quantifiable range of the PCR by plotting the Ct values against the log DNA concentration and performing linear regression analysis. A large number of different food samples (> 100) have been analysed giving good results with this DNA purification method.

The maize reference gene used herein is the maize zein gene.

**PCR amplification.** Purified DNA was used in the amplification reactions. We used a two step PCR amplification approach (see Fig. 1 for a schematic

representation). In the first step we used primers with both a 5'- universal "head" and a gene specific region  

---

(see Table 1 below).

Table 1. Primers and probes used in the PCR reactions\*

Headsequence		5'- TGC TAT GCG CGA GCT GCG - 3'	
Mon 810		Primer/probe name	Sequence (5'-3')
Head primer	Forward	Mon810F1101MH	AAT AAA GTG ACA GAT AGC TGG GCA
	Reverse	Mon810R1101MH	CCT TCA TAA CCT TCG CCC G
Biotinlabeled probe	Forward	Mon810 HH	ACG AAG GAC TCT AAC GTT TAA CAT CCT TTG C
	Reverse	Mon810 Mud1101	GCA AAG GAT GTT AAA CGT TAG AGT CCT TCG T
Bt11		Primer/probe name	Sequence (5'-3')
Head primer	Forward	AHJ-2MH	CGC ACA ATC CCA CTA TCC TT
	Reverse	Bt11 RBMH	GCC TCC CAG AAG TAG ACG TC
Biotin labelled probe	Forward	Bt11 HH	TTT TTA AGA AAC CCT TAC TCT AGC GAA GAT
	Reverse	Bt11 MudF	CCT CTT TTT T
Mud F	Forward	Bt11 MudR	AAG AAA CCC TTA CTC TAG CGA AGA TCC T
	Reverse	Bt11 MudR	AGG ATC TTC GCT AGA GTA AGG GTT TCT T
Bt176		Primer/probe name	Sequence (5'-3')
Head primer	Forward	Cry2 FMH	CCC ATC GAC ATC AGC CTG AGC
	Reverse	PepC-20MH	ATC TCG CTT CCG TGC TTA GC
Biotin labelled probe	Forward	Cry2 RMH	CAG GAA GGC GTC CCA CTG GC
	Reverse	Cry04 (SMT-CT96) MH	GGT CAG GCT CAG GCT GAT GT



Biotin labelled probe Mud F	Bt Syn HH	TTT TTA TGT CCA CCA GGC CCA GCA CGT TTT T
	Bt176 MudF	
	BtSyn2	TCC ACC AGG CCC AGC ACG AAG
	BtSyn3	AGG CCC AGC ACG AAG CCG G
Mud R	Bt176-cryA1-1904	TGA GCA ACC CCG AGG TGG AGG TG
	Bt176 MudR	
	BtSyn2 MudR	CCG GCT TCG TGC TGG GCC TGG TGG A
	Bt176 MudR2504	CAC CTC CAC CTC GGG GTT GCT CA

35 S	Primer/probe name	Sequence (5'-3')
Head primer	Forward 35SH-1	GCT CCT ACA AAT GCC ATC A
	35SMH-F2	GAA GAT AGT GGA AAA GGA AGG TGG C
	35SMH-F3	GGA AAC CTC CTC GGA TTC CAT
	Reverse 35SH-2	KAN IKKE BRUKES
Mud F	35SMH-R1	CCC TTA CGT CAG TGG AGA TAT CAC AT
	35SMH-R2	CTT GCT TTG AAG ACG TGG TTG G
	35SMH-R3	GAT GCT CCT CGT GGG TGG G
	35S MudF	GAA AGG CCA TCG TTG AAG ATG C
Mud R	35S Mud2F	TGC CGA CAG TGG TCC CAA AGA TGG A
	35S MudR	GGC ATC TTC AAC GAT GGC CTT TC
	35S Mud2R	TCC ATC TTT GGG ACC ACT GTC GGC A

Amp	Primer/probe name	Sequence (5'-3')
Head primer	Forward Ampres FMH	TGC TCA CCC AGA AAC GCT G
	Reverse Ampres RMH	TTC TTC GGG GCG AAA ACT CTC
Mud F	Amp pro	GTA AAA GAT GCT GAA GAT CAG TTG GGT GCA
Mud R	Amp MudR	TGC ACC CAA CTG ATC TTC AGC ATC TTT TAC
Nos	Primer/probe name	Sequence (5'-3')
Head primer	Forward Nos FMH	GAA TCC TGT TGC CGG TCT TG

	Reverse	Nos RMH	AAT TTA TCC TAG TTT GCG CGC TA
Mud F		Nos pro	TTT ATG AGA TGG GTT TTT ATG ATT AGA GTC CCG
Mud R		Nos MudR	CGG GAC TCT AAT CAT AAA AAC CCA TCT CAT AAA

IPC	Primer/probe name	Sequence (5'-3')
Synthetic sequence	IPC	CGC AGC GTT TCA AGC AGC ACA TCA TCG ATC TAA
		TCG AGC AGA CGG TAC GAT CAG ACG CTG TCA TAC
		GCA TAA TCG ATA CGC GAT ACT GCC CGC TAA CTG G
Forward	IPC-F	CGC AGC GTT TCA AGC AGC
Reverse	IPC-R	CCA GTT AGC GGG CAG TAT CG
Head	IPC-FMH	CGC AGC GTT TCA AGC AGC
primer		
	Reverse	CCA GTT AGC GGG CAG TAT CG
Mud F	IPC-RMH	AGC AGA CGG TAC GAT CAG ACG CTG T
Mud R	IPC pro	ACA GCG TCT GAT CGT ACC GTC TGC T
	IPC MudR	

Maize Ref gene	Primer/probe name	Sequence (5'-3')
Head	Forward ZM1 FMH	TTG GAC TAG AAA TCT CGT GCT GA
primer		
	Reverse ZM1 RMH	GCT ACA TAG GGA GCC TTG TCC T
Biotin labelled	ZM1 HH	TTT TTC AAT CCA CAC AAA CGC ACG CGT ATT TTT
probe		
Mud F	MudF	CAA TCC ACA CAA ACG CAC G
Mud R	Mud R	CGT GCG TTT GTG TGG ATT G

\* All Head primers contain the head sequence at the 5'- end in addition to the sequences listed

Primers with a "head" were then removed by enzymatic degradation or by transfer of the PCR products to new tubes by capturing DNA onto paramagnetic beads labelled with specific capture probes. In the second PCR step a primer identical to the universal "head" region were used.

In the first PCR step we used 10 pmol of each of the primers, 1 x Dynazyme DNA polymerase reaction buffer, 10 mM dNTP, and 2 µl DynaZyme DNA polymerase (2U µl) in a final volume of 50 µl. In some cases (for Bt11 detection) the concentration of primers was increased. The amplification protocol used was as follows (1. PCR step); 4 cycles using the parameters 95°C for 30s, 55°C for 30 s, and 72°C for 30 s, and then 6 cycles using the parameters 95°C for 30s and 72°C for 30s. Twenty µl of the amplification product from PCR step 1 was treated with 2 µl Exonuclease I to degrade the residual single stranded primers, and 3 µl shrimp alkaline phosphatase to inactivate the nucleotides. The reaction was incubated at 37°C for 30 min, and then at 95°C for 10 min to inactivate the added enzymes.

Five µl of the exonuclease treated products was then used for the second PCR amplification step. 50 pmol of a universal primer identical to the universal region ("head") of the primers used in the first PCR reaction was added. The other components were the same as in the first amplification. The amplification conditions used were: 95°C for 15s and 70°C for 45 s for 40 cycles. During the course of the work some changes and modifications in the PCR conditions were adopted. In the introductory experiments the 2. PCR step was carried out under the following conditions: 40 cycles of 95°C for 15s, 65°C for 15s and 72°C for 30s. Later (pertaining to Fig 3, 4 and 5): the conditions were changed to 95°C for

15s and 70°C for 45s for 40 cycles. In later experiments the same conditions were used but the number of cycles were reduced to 30. In the final experiments the number of cycles in the 1. PCR was reduced to 4, and the number of cycles in the 2 . PCR step again increased to 40.

#### Sequence specific labelling.

After amplification with the "head" primer the amplification products were treated with 2 µl exonuclease I and 2 µl shrimp alkaline phosphatase at 37°C for 30 min, and then 95°C for 10 min to inactivate the enzymes. The cyclic labelling conditions were as follows; 1 x Thermosequenase reaction buffer, 10 pmol of each GM specific probe, 100 pmol ddNTP (except ddCTP), 100 pmol Fluorescein-12-ddCTP, 16 U Thermosequenase DNA polymerase, and 24 µl phosphatase and exonuclease treated PCR product. The labelling was done using the following parameters; 95°C for 15s, 60°C for 1 min for 15 cycles, 95°C for 15s, 55°C for 1 min for 15 cycles, and finally 95°C for 15s, 50°C for 1 min for 15 cycles.

#### DNA array hybridisation.

The format of the assay is shown in Fig. 2. 400 pmol/500µl probes complementary to those used in the labelling reaction were spotted on Gene screen Plus nylon membranes (NEN), and crosslinked for 15 min with a UV transilluminator (Model TL33, UVP Inc., San Gabriel, California). The membranes were prehybridized in 0.5 M Na<sub>2</sub>HPO<sub>4</sub> pH 7.2 and 1 % SDS for 2 hours. The labelled probes were added to 300 µl of 1 x SSC and 6 % PEG 1500 heated to 80°C for 5 min. The hybridisation was done over-night at room temperature with agitation in a Cross Blot Dot Blot hybridisation chamber (Sebia, Moulinaux, France). The membrane was subsequently rinsed in 1 x

SSC, 1 % SDS for 5 min, then 5 min in 0.1 x SSC, 0.1 % SDS, and finally 5 min in 0.1 M Tris-HCl pH 7.5 and 0.15 M NaCl (antibody buffer). At this point the fluorescence was detected directly using a Typhoon scanner (Amersham-Pharmacia). The membranes were then blocked in for 1 hours in blocking buffer: antibody buffer containing 1 % skimmed milk (Difco, Detroit, Michigan). Blocking buffer containing 1/500 antifuorescein HRP-conjugate was then added, and the hybridisation continued at room temperature for 1 hours. Finally, the membranes were rinsed for 30 min in antibody buffer, and the signals detected with 4 CN Plus chromogenic substrate according to the manufacturers recommendations (NEN).

Quantification of scanned signals was carried out using the Imagemaster™ Array software version 2.0 program and calculations were done with Microsoft Excel 97 SR-2.

**Example 1. Qualitative multiplex detection.**

This example shows that qualitative multiplex detection is possible. The multiplex method was used to detect Bt11 corn (DNA from 2 % reference material), Bt176 corn (1%) and Mon810 corn (1%) alone or in combinations (Fig. 3). A corn reference gene detection system was also included to detect corn DNA as such. Each sample was analysed with 2 parallels.

**Example 2. Quantitative nature of the PCR assay.**

This example shows the quantitative nature of the PCR. Bt11 DNA was diluted with non-GM corn DNA to give different GM concentrations. These were analysed using the multiplex assay (Fig. 4). The signals could be

detected directly by fluorescence scanning (not shown) or after enzymatic enhancement (Fig. 4). The gradually fading signals as the concentration of GMO decreases show that the assay is quantitative.

**Example 3. Eight plex detection of GM maize constructs.**

1% Bt176 and 2 % Bt11 DNA was detected in an eight-plex reaction (Fig. 5). For Bt176 we obtained signals from the Bt176 construct specific target, the amp target, 35S promoter and maize specific reference gene and finally from the IPC control. The Bt11 sample gave signals with the Bt11 construct specific PCR, the NOS terminator, the 35S promoter and the maize reference gene in addition to the IPC. Weak signals were (and are essentially always) obtained with the amp primers even when no amp resistance genes from GMOs are present. This is probably due to contamination with amp resistance gene from the DNA polymerase preparation.

**Example 4. Quantitative nature of the 8-plex PCR and the effect of removing the "head primers" after the 1. PCR step.**

This experiment was done to show that it is necessary to remove the "headprimers" after the 1. PCR step to maintain the quantitative nature of the assay. Quantitative 8-plex PCR for detection of GMP corn was carried out. Bt176 DNA and Bt11 DNA were kept constant at 0.7 % in all samples. Concentrations of Mon810 DNA was varied from 2.0 to 0 %. In Fig. 6A, the PCR was carried out in two steps: 1. PCR (10 cycles) using specific primers with a common "head" sequence. Primers were then digested and the 2. PCR (30 cycles) is carried

out using the common head primer. Fig. 6B shows the same as Fig. 6A except that the specific primers were not degraded before the 2. PCR step. Fig. 6A shows clearly the quantitative nature of the assay as the Mon810 DNA signal is gradually fading as the concentration decreases. Even though the Mon810 signals are decreasing in Fig 6B, it is easily seen that the overall results are dramatically influenced by not removing the "head primers" after the 1 PCR step. The relative signal strength from the different PCRs is changed and the signals are generally weaker. This is most probably caused by different amplification efficiencies of the specific primers with the headsequence and formation of primer dimers.

**Example 5. Effect of omitting the 2. PCR step.**

This example showed the effect of omitting the 2. PCR step (Fig. 7). The experiment was the same as in Example 4 (Fig. 6A) except that the 1. PCR step using specific primers with head sequence was extended to 40 cycles and the 2. PCR step was omitted. As in example 4, Fig. 6B performing the PCR with the headprimers present leads to different amplification efficiencies for the different PCRs and some fragments (e.g. Bt176 and Bt11) were not amplified.

**Example 6. The effect of diluting the template DNA.**

A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810 at different dilutions was used as templates in the PCR (Fig. 8). We see that the signals gradually fade as the template DNA is diluted, but that the dilution effect is relatively small down to 16 fold dilution.

**Example 7. Quantitative detection of Mon810 alone and together with Bt11.**

A dilution series containing different amounts of Mon810 DNA was analysed alone and in combination with 1% Bt11 in the samples. The fluorescence signals after hybridisation of the labelled probes and the blot after HRP colouring are shown in Fig. 9. The fading of the Mon810 signals as the amount of Mon810 DNA is lowered is clearly visible. The 35S signal decreases in A down to zero as expected and down to a fixed level caused by the presence of Bt11 DNA in B. The other signals remain constant. The fluorescence signals from Mon810 (Fig. 9 panel I) were quantified and plotted against the given concentrations (Fig. 10). A linear response was observed up to 5 % Mon810. Little difference was observed between parallels. The signal strengths remained the same whether Bt11 DNA was present or not.

**Example 8. Quantitative detection of Mon810 alone and together with Bt11 (repetition).**


To investigate the repeatability of the system, the experiment in example 7 was repeated. A dilution series containing different amounts of Mon810 DNA was analysed alone and in combination with 1% Bt11 in the samples. The fluorescence signals and the blot after HRP colouring are shown in Fig. 11. The fading of the Mon810 signals as the amount of Mon810 DNA is lowered is again clearly visible, although the signals have reached some degree of saturation and the difference between signals at higher concentrations of Mon810 is smaller. The 35S signal decreases in A down to zero as expected and down




to a fixed level caused by the presence of Bt11 DNA in B. The other signals remain constant. The fluorescence signals from Mon810 were again quantified and plotted against the given concentrations (Fig. 12). An almost linear response was observed up to 2 % Mon810. The signal at 5% Mon810 was lower than expected probably due to saturation of the probe (all probe molecules were already labelled). The difference between parallels were greater than at example 7. Again the signal strengths remained the same whether Bt11 DNA was present or not.

**Example 9. Quantitative detection of Bt176 alone and together with Mon810.**


The experiment was performed as in example 6, except that the amount of Bt176 was varied and Mon810 was kept constant. A dilution series containing different amounts of Bt176 was analysed alone and in combination with 1% Mon810 in the samples. The fluorescence signals and the blot after HRP colouring are shown in Fig. 13. The fading of the Bt176 signals as the amount of Bt176 DNA is lowered is clearly visible. The 35S signal and the amp signal decrease in A down to zero as expected. 35S decreases down to a fixed level caused by the presence of Mon810 DNA in B. The other signals remain constant. The fluorescence signals from Mon810 were again quantified and plotted against the given concentrations (Fig. 14). Also here a (close to) linear response was observed.




**Figure 1.** Schematic representation of the quantitative multiplex amplification method. (A): In the first PCR step, the targets are amplified with primers containing "heads" that are equal for all the targets. (B): The "head"-containing primers are then removed by enzymatic digestion (left) or the amplified products are hybridized to an internal biotinylated capture probe and the complex is then purified through binding to biotinylated paramagnetic beads (right). These are two independent alternative purification strategies. (C): In the second PCR step, a primer identical to the "head" sequence is used.




**Figure 2.** The test format is schematically illustrated. The probes complementary to the labelled test probes used in the enzymatic labelling are spotted horizontally using a grid. During hybridisation the grid is turned 90 degrees before application of hybridisation solutions labelled probes.




**Figure 3.** Multiplex detection of GMO corn samples. GM corn DNA was analysed either alone or in combinations. Line 1: detection of the corn reference DNA, line 2: Mon810 signals, Line 3: Bt11 signals, Line 4: Bt176 signals. The samples analysed are indicated under the corresponding lanes (all analyses in duplicate), Lane 1,2: non GMO maize, lane 3, 4: 0.4 % Bt176, 0.7 % Bt11 and 0.4% Mon810 DNA, lane 5, 6: 1% Bt11 and 0,5% Bt176, lane 7, 8: 1% Mon810, lane 9,10: 1% Bt176, lane 11, 12: 2% Bt11.



**Figure 4.** Quantitative chromogenic detection of Bt11 corn DNA using the multiplex assay. 2% Bt11 corn DNA was diluted in non GM corn DNA to give different concentrations of GM corn. The results show the quantitative response of the assay as the concentration of GM corn is lowered. The first line shows the corn DNA reference signals, the second row shows the Bt11 signals. The signals were recorded on a Typhoon scanner, PE systems. ;




**Figure 5.** Eight-plex detection of GM maize. Eight specific primer pairs with "heads" were used in the first PCR step. The lines represent (from above): Bt 176, Bt11, Mon810, amp, Nos terminator, 35S promoter, Internal PCR control (IPC) and maize reference gene.




**Figure 6.** Quantitative multiplex PCR for detection of GMP corn and the necessity of removing primers after the 1. PCR step. Each line shows the detection of a specific PCR product as indicated to the left. Each lane (a through l) represent different samples. All samples (a-j) contained a mixture of 0.7 % Bt176 and 0.7 % Bt11. In addition Mon 810 corn DNA was added to 2.0 % (lanes a, b), 1.0 % (lanes c, d), 0.5 % (lanes e, f), 0.2 % (lanes g, h) and 0.0 % (lanes i, j). In addition all lanes (a-l) contained approx. 100 copies of an internal positive control (IPC) DNA. Amp: ampicillin resistance gene from the pUC18. Nos: Nos terminator, 35S: Cauliflower mosaic virus promoter.

(A): PCR carried out in two steps: 1. PCR (10 cycles) using specific primers with a common "head" sequence. Primers are then digested and the 2. PCR (30 cycles) is carried out using the common head primer. (B) Same as A, but the specific primers were not degraded before the 2.PCR step. Panel I: shows the fluorescence signals after hybridisation and scanning, panel II: shows the blot after binding of antibodies and enzymatic HRP colour reaction.




**Figure 7.** The effect of omitting the 2. PCR step. Same as in Fig. 6A, except that the 1. PCR step using the specific primers with head sequence was extended to 40 cycles and the 2. PCR step was omitted. Panel A shows the fluorescence signals after hybridisation and scanning, panel B shows the blot after binding of antibodies and enzymatic HRP colour reaction.






**Figure 8.** The effect of diluting the templat DNA. A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810 at different dilutions was used as templates in the PCR. Panel I shows the fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 1,2: undiluted DNA template, lanes 3, 4:  $\frac{1}{4}$  dilution, lanes 5,6:  $\frac{1}{16}$  dilution, lane 7, 8:  $\frac{1}{64}$  dilution, lanes 9,10:  $\frac{1}{256}$  dilution, lanes 11,12: no tamplate added.


9/14



**Figure 9.** Quantitative 8-plex detection of Mon810 DNA alone (A) or together with 2 % Bt11 DNA (B). Panel I shows the fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 01, 02: A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810. Lane 1a, 1b: 5% Mon810, lanes: 2, 3: 2% Mon810, lanes 4, 5: 1.0 % Mon810, lanes 6, 7: 0.5% Mon810, lanes 8, 9: 0.1% Mon810, lanes 10, 11: 0 % Mon810, lanes 12, 13: IPC (date 020901).




**Figure 10.** The relationship between amount of Mon810 maize in a sample and the signal strength. The Mon810 fluorescence signals in Fig.9 panel I, were quantified using Imagemaker program and plotted against the given concentration of the samples.




**Figure 11.** Quantitative 8-plex detection of Mon810 DNA alone (A) or together with 2 % Bt11 DNA (B). Repetition of example,6 (Fig. 9). Panel I shows the fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 01, 02: A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810. Lane 1a, 1b: 5% Mon810, lanes:2, 3: 2% Mon810, lanes 4, 5: 1.0 % Mon810, lanes 6, 7: 0,5% Mon810, lanes 8, 9: 0,1% Mon810, lanes 10, 11: 0 % Mon810, lanes 12, 13: IPC (date 130901).


12/14



**Figure 12.** The relationship between amount of Mon810 maize in a sample and the signal strength. The Mon810 fluorescence signals from the experiment in Fig.11 were quantified using Imagemaker program and plotted against the given concentration of the samples. The average of 2 parallels are shown.



**Figure 13.** Quantitative 8-plex detection of Bt176 DNA alone (A) or together with 1 % Mon810 DNA (B). Panel I shows the fluorescence signals after hybridisation and scanning, panel II shows the blot after binding of antibodies and enzymatic HRP colour reaction. Lanes 1, 2: A reference mixture of 0.7% Bt176, 0.7% Bt11 and 0.7% Mon810. Lane 3, 4: 2% Bt176, lanes: 5, 6: 1% Bt176, lanes 7, 8: 0.5 % Bt176, lanes 9, 10: 0.2% Bt176, lanes 11, 12: 0.1% Bt176, lanes 13, 14: 0 % Bt176, lanes 15, 16: IPC (date 060901)



**Figure 14.** The relationship between amount of Bt176 maize in a sample and the fluorescence signal strength. The Bt176 fluorescence signals from the experiment in Fig.13 were quantified using Imagemaker program and plotted against the given concentration of the samples. The average of 2 parallels are shown.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**